Tango Therapeutics (TNGX) CFO receives 40,000 RSUs and 240,000 options

Rhea-AI Filing Summary

Tango Therapeutics, Inc.’s Chief Financial Officer Matthew Gall received new equity-based compensation. He was granted 40,000 shares of Common Stock in the form of restricted stock units, which represent rights to receive an equal number of shares as they vest over time.

The RSUs vest over three years: 13,200 units on or about May 10, 2027, 13,200 on or about May 10, 2028, and 13,600 on or about May 9, 2029, subject to continued service. He was also granted stock options for 240,000 shares of Common Stock at an exercise price of $20.98 per share, vesting 25% on April 15, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, also contingent on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gall Matthew

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	240,000	$0.00	--
Grant/Award	Common Stock	40,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 240,000 shares (Direct, null); Common Stock — 40,000 shares (Direct, null)

Footnotes (1)

1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest over a three-year period at a rate of (i) 13,200 RSUs on or about May 10, 2027, (ii) 13,200 RSUs on or about May 10, 2028 and (iii) 13,600 RSUs on or about May 9, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option shall vest and become exercisable over a four-year period, at a rate of 25% on April 15, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Key Figures

RSU grant size: 40,000 shares Option grant size: 240,000 shares Option exercise price: $20.98/share +4 more

7 metrics

RSU grant size 40,000 shares Restricted stock units representing Common Stock granted to CFO

Option grant size 240,000 shares Stock options for Common Stock granted to CFO

Option exercise price $20.98/share Exercise price for 240,000 stock options

RSU vesting 2027 13,200 RSUs Vest on or about May 10, 2027, subject to continuous service

RSU vesting 2028 13,200 RSUs Vest on or about May 10, 2028, subject to continuous service

RSU vesting 2029 13,600 RSUs Vest on or about May 9, 2029, subject to continuous service

Option initial vesting 25% on April 15, 2027 First tranche of option vesting, remaining monthly thereafter

Key Terms

restricted stock units, vest, Stock Option (Right to Buy), exercise price, +1 more

5 terms

restricted stock units financial

"These shares are represented by restricted stock units (the "RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vest financial

"The RSUs shall vest over a three-year period at a rate of..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price": "20.9800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"subject to the Reporting Person's continuous service with the Issuer"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gall Matthew

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		A		40,000(1)	A	$0	40,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20.98	05/01/2026		A		240,000		(2)	05/01/2036	Common Stock	240,000	$0	240,000	D

Explanation of Responses:

1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest over a three-year period at a rate of (i) 13,200 RSUs on or about May 10, 2027, (ii) 13,200 RSUs on or about May 10, 2028 and (iii) 13,600 RSUs on or about May 9, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

2. This option shall vest and become exercisable over a four-year period, at a rate of 25% on April 15, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Julie Fogarty, as attorney-in-fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tango Therapeutics (TNGX) CFO Matthew Gall report in this Form 4?

He reported equity awards from Tango Therapeutics: 40,000 restricted stock units and stock options for 240,000 shares at an exercise price of $20.98 per share, all granted as compensation and subject to multi‑year vesting and continued service conditions.

How many Tango Therapeutics (TNGX) RSUs were granted to the CFO and how do they vest?

Matthew Gall received 40,000 restricted stock units. These RSUs vest over three years: 13,200 on or about May 10, 2027, another 13,200 on or about May 10, 2028, and 13,600 on or about May 9, 2029, assuming he remains continuously employed.

What stock options did Tango Therapeutics (TNGX) grant its CFO in this Form 4?

The CFO received stock options for 240,000 shares of Common Stock with a $20.98 per share exercise price. The options vest 25% on April 15, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.

Are the Tango Therapeutics (TNGX) Form 4 transactions open‑market buys or compensation grants?

These transactions are compensation-related grants, not open‑market purchases or sales. Both the 40,000 RSUs and the 240,000 stock options are coded as awards (transaction code A) and vest over time, contingent on the CFO’s ongoing service.

What are the post-transaction holdings reported for Tango Therapeutics (TNGX) CFO Matthew Gall?

After these awards, the Form 4 shows 40,000 shares of Common Stock represented by RSUs and 240,000 stock options as directly held positions, each subject to their respective vesting schedules before the underlying shares can be fully accessed or exercised.

What conditions affect vesting of the Tango Therapeutics (TNGX) CFO’s new RSUs and options?

Both awards require continuous service with Tango Therapeutics through each vesting date. RSUs vest in three annual tranches through 2029, while options vest 25% in April 2027 and monthly thereafter, so leaving early could prevent unvested portions from being earned.